API | fluspirilene

fluspirilene Report issue

Small molecule Experimental

AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Fluspirilene is a diphenylbutylpiperidine typical antipsychotic drug, used for the treatment of schizophrenia. It is administered intramuscularly. It was discovered at Janssen Pharmaceutica in 1963. A 2007 systematic review investigated the efficacy of fluspirilene decanoate for people with schizophrenia: ^Wikipedia

Chemistry

SMILES: O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2
InChIKey: QOYHHIBFXOOADH-UHFFFAOYSA-N
Mol. Mass: 475.58
ALogP: 5.31 Partition coefficient
ChEMBL Molecule:
fluspirilene

More Chemistry

Pharmacology

Mechanism of Action:
- D(2) dopamine receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

Organizations (2)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (7)

Approved Indications (1)

Schizophrenia

Experimental Indications - Clinical Trial Phases 1-4 (7)

Anxiety Disorders (Phase 3)

Dementia (Phase 3)

Depression (Phase 3)

Psychophysiologic Disorders (Phase 3)

Psychotic Disorders (Phase 4)

Schizophrenia (Phase 4)

Schizophrenia Spectrum and Other Psychotic Disorders (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 2
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue